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Our aims were to analyze reporting of Gleason pattern (GP) 3 and 4 prostate cancer with the 
ISUP 2005 Gleason grading and to collect consensus cases for standardization. We scanned 
25 prostate biopsy cores diagnosed as Gleason score (GS) 6-7. Fifteen genitourinary 
pathologists graded the digital slides and circled GP 4 and 5 in a slide viewer. Grading 
difficulty was scored as 1-3. GP 4 components were classified as Type 1 (cribriform), 2 
(fused) or 3 (poorly formed glands). A GS 5-6, 7 (3+4), 7 (4+3), 8-9 was given in 29%, 41%, 
19% and 10% (mean GS 6.84, range 6.44-7.36). In 15 cases, at least 67% of observers agreed 
on GS groups (consensus cases). Mean interobserver weighted kappa for GS groups was 0.43. 
Mean difficulty scores in consensus and non-consensus cases were 1.44 and 1.66 (p = 0.003). 
Pattern 4 Types 1, 2 and 3 were seen in 28%, 86% and 67% of GP 4. All three co-existed in 
16% (11% and 23% in consensus and non-consensus cases, p = 0.03). Average estimated and 
calculated %GP 4/5 were 29% and 16%. After individual review, the experts met to analyze 
diagnostic difficulties. Areas of GP 4 and 5 were displayed as heat maps, which were helpful 
for identifying contentious areas. A key problem was to agree on minimal criteria for small 
foci of GP 4. In summary, the detection threshold for GP 4 in NBX needs to be better defined. 










In 2005 the International Society of Urological Pathology (ISUP) organized a consensus 
conference on Gleason grading of prostate cancer [1]. Since its inception in the 1960s, the 
Gleason grading has undergone a gradual transition in its practical application. The purpose of 
the meeting was to reach a consensus as to how the grading system should be used in needle 
biopsy (NBX) and radical prostatectomy (RP) specimens. The conference addressed issues in 
the interpretation of morphological patterns and how to summarize and report grade 
information.  
 
It is not clear how the ISUP revision of Gleason grading has affected the pathology 
community. Multiple studies were performed on grading reproducibility in the years prior to 
the ISUP consensus conference [2-6], but it is unknown how reproducible the modified 
Gleason grading is among experts in urological pathology. There is also a need to set a 
standard among general pathologists in application of the new guidelines.  
 
In previous reproducibility studies on prostate cancer grading, the observers assigned Gleason 
scores, but to our knowledge no attempts were made to analyze which areas the grading 
decisions were based upon. In this study, 15 experts in urological pathology were asked to 
circle areas of Gleason patterns (GP) 4 and 5. This enabled an analysis of how grading 
decisions are made and identification of controversies and agreements that are not reflected by 
the Gleason scores (GS) alone. The aims were both to assess reproducibility and to better 
define the critical transition between GP 3 and 4. Interpretation difficulties were analyzed. 
Our purpose was not only to study areas of disagreement but also to collect consensus cases 
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for standardization of grading. By publication of such cases, it is possible to minimize the 




Materials and Methods 
 
 
A total of 220 prostate NBX cases were reported at the Karolinska University Hospital, 
Stockholm, Sweden in January and February 2008, 99 of them as prostate cancer. A set of 
NBX cores diagnosed as GS 6-7 prostate cancer was selected. Only GS 6 cases that were 
borderline to GS 7 were included, i.e. cases in which a GS 7 or higher theoretically might be 
diagnosed. One representative core was chosen from each of 30 biopsy sets, recut and stained 
with hematoxylin and eosin. The slides were reviewed by one of the authors (L.E.). Cases 
with technical artifacts were omitted and 27 slides were scanned in a digital slide scanner 
(CCITI, Dijon, France). Among them two were excluded because of unsatisfactory image 
quality, leaving 25 digital slides for analysis.  
 
Fifteen experts in urological pathology from 11 countries were invited to participate: Austria 
(1), Canada (1), Denmark (1), France (3), Germany (1), Italy (1), Portugal (1), Spain (2), 
Sweden (1), Switzerland (1) and the United Kingdom (2). The experts were asked to assign 
primary and secondary Gleason grades to the digital slides and a GS was automatically 
generated. Grading difficulty was scored as 1-3. Score 1 meant that in the expert's opinion 
only one GS was possible, score 2 that another GS was considered but the pathologist was 
convinced that the selected GS was the best choice and score 3 meant that the observer was 
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uncertain if the selected GS was the best score and another score would also be acceptable. 
GP 4 components were classified as Type 1 (cribriform), 2 (fused) or 3 (poorly formed 
glands) (Figure 1A-C). Each expert circled areas of GP 4 and 5 in the slide viewer and were 
asked to estimate percentage of GP 4 and 5. These percentages were also calculated from the 
circled areas. In the image analyzer, the circled areas were layered on top of each other to 
obtain a summation area, similar to a heat map showing the frequency with which a certain 
GP was assigned within the biopsy core (Figure 1D-F). The darker the color, the more often a 
GP had been assigned. Green was used for GP 4 and yellow for GP 5. GP 3 was not marked 
on the digital slides. 
 
After individual review, 11 of the experts met in Paris in October 2009 to analyze diagnostic 
difficulties and agree on a set of consensus cases (L.B.G., P.C., E.C., D.B., L.E., R.G., G.K., 
C.L., P.O., B.V., M.V.). The grades were analyzed by individual Gleason scores and by GS 





Unpaired Student’s t-test was used for comparison of means and chi-2 test for comparison of 
proportions. A p value less than 0.05 was considered significant. Unweighted and weighted 






The original GS distribution was 6 (10, 40%), 3+4=7 (11, 44%), 4+3=7 (4, 16%), respectively 
(mean 6.6). The 15 experts assigned a GS of 5 (4, 1%), 6 (106, 28%), 3+4=7 (154, 41%), 
4+3=7 (72, 19%), 8 (24, 6%) and 9 (15, 4%), respectively (mean 6.84, range 6.44-7.36). The 
observers reported a GS of 5 in 0-12%, 6 in 0 -52%, 7 in 44-100%, 8 in 0-24% and 9 in 0-
16%.  
 
The unweighted kappas of presence of GP 4 and 5 were 0.54 and 0.81, respectively. The 
weighted kappas of Gleason scores 5-9 and of the GS categories 5-6, 3+4=7, 4+3=7, 8 and 9 
were 0.35 and 0.43, respectively. 
 
An average of 74% of the experts agreed on the most commonly assigned GS (5, 6, 7, 8 or 9) 
with a range of 47-93% in the 25 cases. A 100% concordance was not reached for any of the 
cases either for the Gleason scores or the GS categories. A concordance of at least 80% was 
obtained in 12 cases for Gleason scores and in 6 cases for the GS categories. A concordance 
of at least 67% was obtained in 19 cases for Gleason scores. In 15 cases there was a 
concordance of at least 67% for the GS categories 5-6, 3+4=7, 4+3=7, 8 and 9 and these were 
designated as consensus cases. Their Gleason scores were 6, 3+4=7 and 4+3=7 in 6, 7 and 2 
cases, respectively (Table 1). A concordance of 33-60% was reached for GS categories in 10 
cases, which were designated as non-consensus cases (Table 2). In one of these cases the 
spread of GS was from 6 to 9 and in two other cases from 6 to 8.  
 
Difficulty scores were reported by 13 of the 15 observers. A difficulty score of 1, 2 or 3 was 
assigned in 58%, 32% and 10%, respectively (Table 2). The average reported difficulty score 
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was 1.53 (range 1.20-1.88 among 13 observers). Eight observers had a median difficulty score 
of 1 and 5 had a median score of 2. In the 15 consensus cases the average difficulty score was 
1.44 as compared to 1.66 in the 10 non-consensus cases (p = 0.003). Among consensus cases 
a difficulty score of 1, 2 or 3 was assigned in 65%, 27% and 8%, respectively. Among non-
consensus cases a difficulty score of 1, 2 or 3 was assigned in 48%, 38% and 14%, 
respectively. When biopsies were assigned a difficulty score 3, 53% (18 of 34) were non-
consensus cases compared to 33% (62 of 188) when a score 1 was assigned (p = 0.026).  
 
Thirteen observers categorized the GP 4 according to type. GP 4 Type 1 (cribriform), 2 
(fused) or 3 (poorly formed glands) were seen in 20%, 61% and 47%, respectively (Table 4). 
A GP 4 was reported in 70% (228 of 325). When a GP 4 was reported, Types 1, 2 and 3 were 
seen in 28%, 86% and 67%. When a GP 4 was reported, all three patterns, two patterns and 
one pattern were seen in 16%, 50% and 34%, respectively (Table 5). All three patterns were 
seen in 11% of the consensus cases and 23 % of the non-consensus cases (p = 0.03). Per case, 
1.88, 6.88 and 2.56 observers assigned a GP type of 1, 2 and 3, respectively. A GP 5 was 
assigned by at least one observer in seven cases (by one to eight observers). 
 
Regions were marked by 14 of 15 observers. The precision of marking the areas was highly 
variable. The mean percentage of GP 4 cancer was 28% when estimated subjectively and 16% 
when calculated by the image analyzer. The mean percentage of GP 5 was 0.5% as estimated 
and 0.1% as calculated. 
 
Areas of GP 4 and 5 were displayed as heat maps with overlaying regions. The maps were 
helpful for identifying contentious areas. A key problem was to agree on minimal criteria for 
small foci of GP 4 (Figure 2). In an open discussion, areas were identified where the majority 
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had overlooked a minute component of cancer that might be interpreted as high-grade 
carcinoma. These included occasional solid strands (Figure 2A-B) or fusion patterns (Figure 
2C-D) in GS 3 + 3 = 6, which could be considered tangential sections of GP 3 cancer glands. 
In other cases, such structures were too abundant to be overlooked (Figure 2E-F), leading to 





Over the past decades there has been a gradual change of the practice of Gleason grading, 
causing considerable grade shift upwards [7]. The recent ISUP revision of the Gleason 
grading system has contributed to this upgrading. Helpap et al. showed that the number of 
NBX cases diagnosed as GS 6 decreased from 48% to 22% when adopting the ISUP 
modification of Gleason grading, while the number of GS 7 cases increased from 26% to 68% 
[8]. In a recent study by Delahunt et al. on patients with locally advanced prostate cancer, the 
number of cases diagnosed as GS 6 decreased from 11% to 5% when going from conventional 
to ISUP modified GS [9]. 
 
Reasons for upgrading include both changed pattern interpretation and new recommendations 
for how to report the GS on NBX specimens. The ISUP guidelines proposed that GP 1 should 
be avoided 'with extremely rare exception', that GS 2+2= 4 should rarely be diagnosed on 
NBX and that most cribriform cancers should be diagnosed as GP 4 rather than 3 [1]. 
Furthermore, cancers with incomplete, poorly formed glands were now included in GP 4. 
Some of these rules for pattern interpretation were implemented by many experts already 
before the ISUP revision. Perhaps more important, there was previously a widespread 
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tradition to overlook small foci of higher grade or to diagnose them as tertiary pattern of 
higher grade, but not include them in the GS. Prior to the ISUP consensus meeting a GP of 
higher grade was generally included only if more than 5% of all cancer present [10]. One of 
the key recommendations of the ISUP meeting was that even minute foci of higher grade 
should be included in the GS on NBX specimens, regardless of the extent though it was added 
they should be identified at ‘low to medium power’. This possible equivocation has probably 
meant that, pathologists may have different detection thresholds for small high-grade 
components and there is a need to standardize this interpretation. In retrospect, this part of the 
ISUP revision of Gleason grading can be questioned. The consequences have evidently been a 
substantial upgrading in some institutions. There is now considerable uncertainty among 
pathologists where to place the threshold for recognition of minute high-grade components. 
There is also a concern among urologists how a GS 7 cancer on needle biopsy should now be 
treated. It would have been very helpful if the ISUP consensus meeting 2005 had presented 
more precise practical guidelines regarding GP 4 detection with e.g. ample illustrations. The 
best that can be done in the current situation is that experts attempt to agree on a standardized 
interpretation of the GP 3 to 4 transition. As a first step we aim to use the microphotograph 
material from this study to set up a web-based image library that is made accessible for 
European pathologists. 
 
The weighted kappa of Gleason scores in the present study was lower than reported in many 
previous studies on interobserver reproducibility of Gleason grading [2, 3, 5, 6]. However, the 
results are not comparable as the biopsy cores of the present study were selected to include 
borderline cases between GS 6 and 7. The unweighted kappas of presence of GP 4 and 
particularly of GP 5 were far better. The latter may be an over estimation as the cases were 
primarily selected to lack a GP 5 component. There are indeed multiple pitfalls with the use of 
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kappa statistics. How study cases are selected is of critical importance. The safest method to 
avoid selection bias is to use a consecutive series. Unfortunately, it is not feasible to make 
such a study on a consecutive series that is sufficiently large to include difficult and 
interesting cases. More commonly, there is an accumulation of cases that experts consider 
unequivocal so the golden standard of the study cannot be criticized. By contrast, in the 
present study, we have selected cases with borderline morphology. The easiest cases of GS 6 
were excluded and only GS 6 cases where it was thought that someone might diagnose a GS 7 
were included. We have also refrained from inclusion of classical GS 9-10 cases, which 
would also most likely give a high grading reproducibility. Thus, it is not surprising that the 
kappa statistics in our study were comparatively low and they should rather be used for 
comparisons within the study. 
 
We here used digitized slides that were read in a slide viewer. It has been shown that the 
diagnostic accuracy using digital slides is similar to conventional glass slides [11]. It would 
not have been possible to circulate glass slides to 15 experts in 11 countries within a 
reasonable time frame. The other advantage with digital slide is that they allow marking of 
regions of interest. To our knowledge this is the first attempt to identify the areas that Gleason 
grading decisions are based upon. The advantage of the heat map system is that it enables an 
analysis of which patterns are controversial and which are easier to grade. After an 
independent assessment of grades a majority of the group met in Paris to discuss controversies 
and analyze why there was disagreement in some cases. In the discussion the heat maps could 
be removed from the digital slides to show the detailed histological morphology. While doing 
this we compared morphological features with lists of individual grading results. It was 
sometimes evident that disagreement was caused by an occasional outlier, while in other 
cases, the participants were split into more equal groups of different standpoints. Certain 
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patterns seemed to be more difficult than others, such as incomplete glands where the 
detection threshold was critical for accurate grading. 
 We found that there is not only a variability in how Gleason scores are assigned but also in 
terms of what precise areas decisions are based on. When minute foci of higher grade should 
be included in the GS on NBX specimens, regardless of the extent, it is necessary to define a 
detection threshold in order to avoid the degeneration of Gleason grading into a three-tiered 
grading system running from GS 7 to 9. In the open discussion, such examples were found to 
include possible tangential cuts of complete or incomplete glandular structures.  
 
Fusion pattern was found to be the most common GP 4 type, while cribriform cancer, i.e. one 
of the classical variants of GP 4, was least common. A novel feature of the ISUP revision is 
that poorly formed or incomplete glands are included in GP 4, which is in line with the 
general concept of GP 4 as cancer that attempts to form glands, yet falls short of forming 
complete, circumscribed glands. Poorly formed glands were seen in 47% of GP 4, making it 
the next most common type of GP 4 after the fusion pattern. All three patterns were seen in 
16% of GP 4 cases, more commonly in non-consensus cases than in consensus cases, 
indicating that the presence of a heterogeneous GP 4 component adds to the grading 
difficulty. 
 
The purpose of the study was primarily to define the transition between Gleason patterns 3 
and 4 and the cases were selected accordingly. Yet a GP 5 was assigned by at least 1 observer 
in 7 cases (by 1 to 8 observers). In a study by Egevad et al., a questionnaire was distributed to 
91 genitourinary pathologists in countries around the world [12]. Rare individual cells, 
strands, or nests identified only at less than 40x lens magnification were considered sufficient 
to diagnose GP 5 on needle biopsy by 17% of pathologists, whereas 83% required clusters of 
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such structures seen at lower than 40x magnification. The GP 5 identified by occasional 
observers in some cases proved to be minute components rather than cohesive areas and 
should be overlooked according to the vast majority of observers. 
 
Interestingly, cases with higher self-rated grading difficulty had lower reproducibility. A 
difficulty score of 1, 2 or 3 was assigned in 58%, 32% and 10%, respectively, which means 
that as many as 42% of assessments were accompanied with a certain degree of doubt as to 
the correct grade. It is on the other hand surprising that in 42% of non-consensus cases, the 
experts gave a difficulty score of 1, i.e. they were absolutely certain that their grade was the 
correct one. Thus, there is a discrepancy between our self-confidence and the performance as 
a group. These results have to be interpreted with some caution as a research study differs 
from routine pathology work. A limited number of cases are reviewed and the participants are 
usually devoted to the task. A certain fear to deviate from the midstream of the group may add 
to the motivation. Thus, study participants are more likely to report a high self-rated grading 
difficulty in cases where they fail to  reach consensus, while in a busy routine practice, 
mistakes may also be done in cases that are felt to be easy. 
 
 
Percent high-grade cancer (%GP 4/5) has been suggested as a prognostic factor for prostate 
cancer [13-16]. The Gleason grading system was originally a nine-tiered system, but only 
some of the grades are actually commonly used. Therefore, %GP 4/5 may help to separate 
cases in the mid range of the Gleason scores. A ‘sliding scale’ grading system, similar to 
nomograms has attractions over a stochastic grading system, which can fall prey to the 
problems exemplified by this study. The present study is to our knowledge the first time a 
comparison has been done between subjective and objective assessment of %GP 4/5. 
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Interestingly, the subjectively estimated area was almost twice as large as the objective 
measurement. This may be explained by some inherent difficulties in the assessment of 
proportions of GPs. Prostate cancer specimens contain a mixture of malignant and benign 
glands and also of epithelial and stromal components. When there are multiple GPs present, 
eg. GP 3 and GP 4, they are often mixed. The assessment of areas occupied by a certain GP is 
thus not quite straight-forward. It may vary between individuals how much of non-cancerous 
elements within the tumor we include or subtract. The higher percentages by subjective 
assessment may indicate that the human eye tends to overlook presence of eg. occasional GP 
3 glands within a GP 4 or the presence of benign glands within the tumor. When we are asked 
to document our assessment by outlining a high-grade component digitally, it seems to make 
us more aware of such non-high-grade components. On the other hand, the subjective 
estimation of %GP 4/5 has been shown to be at least as reproducible as that of the GS. In an 
interobserver reproducibility study, 4 observers had a mean weighted kappa for biopsy GS 
and %GP 4/5 of 0.48 to 0.55 (overall mean 0.51) and 0.52 to 0.68 (overall mean 0.60), 
respectively [17]. However, it was found that we subjectively over estimate %GP 4/5 as 
compared to computerized calculation of the percentage. A difficulty in the assessment of 
percentages of Gleason patterns is that malignant glands are often mixed with stroma and 
benign glands and it is difficult to know how much of intervening tissues that should be 
subtracted.  
 
The clinical performance of GS as predictor of outcome is evidently most important when 
determining the optimal definition of grade. Billis et al. showed that both conventional and 
modified GS on NBX predicted outcome after RP [18]. A lower p value was obtained with the 
modified GS and the authors concluded that the conventional grading was outperformed. 
However, the Kaplan Meier curves for GS 6 and 7 were almost identical with modified 
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grading and the separation seems to be between GS 7 vs. 8 or higher. Delahunt et al. recently 
questioned the performance of the modified GS as predictor of disease progression [9]. 
Further studies are needed and it is important that those studies clearly define how the GS was 
obtained. A major disadvantage of the ISUP 2005 revision of the Gleason grading system was 
that it did not include any validation studies comparing the revised and the conventional 
versions of this grading system. 
 
Perhaps the most useful part of this study was the identification of a set of 15 cases in which 
there was a 67% consensus among experts in terms of GS categories. This set of cases may 
serve as a library for standardization among general pathologists. For this purpose, we intend 
to use the European Network of Uropathology (ENUP), an international network of 
communication recently organized by the Uropathology Working Group of the European 
Society of Pathology (ESP) [19]. The purpose of ENUP is to establish a channel for 
distribution of information about urological pathology such as guidelines, consensus 
documents, meetings and courses, to organize research collaborations and to set up 
mechanisms for survey studies. ENUP has recruited a total of 374 individual members from 
338 pathology laboratories in 15 west European countries. Email is used for all 
communication and studies are carried out through interactive websites. Our intention is to 
invite the ENUP members to use the same set of cases as in the expert study for a larger 
reproducibility study and then give feedback as to how experts agreed on the same cases. 
Thereby, it will be possible to use a library of digital slides for stadardization of 
histopathological grading.  
 
In summary, there is still a considerable disagreement among experts on borderline GS 6-7 
cases, using the ISUP revision of the Gleason grading of prostate cancer. A major source of 
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disagreement is that the detection threshold for minimal foci of GP 4 in NBX needs to be 
better defined. Yet, we were able to identify a set of consensus cases that are likely to be 












Table 1. Fifteen consensus cases with at least 67% agreement for GS categories. Number of 
votes for most commonly assigned grade shown in bold font. 
 
Table 2. There were 10 non-consensus cases with agreement for GS categories in less than 
67%. Number of votes for most commonly assigned grade shown in bold font. 
 
Table 3. Difficulty scores in 15 consensus and 10 non-consensus cases. Score 1 = only one 
Gleason score (GS) was possible, score 2 = another GS was considered but the pathologist 
was convinced that the selected GS was the best choice and score 3 = uncertain if the selected 
GS was the best score. 
 
Table 4a. Gleason pattern (GP) 4 types in consensus and non-consensus cases. GP4 Type 1 = 
cribriform glands, type 2 = fused glands and type 3 = poorly formed glands. Percentages of all 
cases.  
 
Table 4b. Gleason pattern (GP) 4 types in consensus and non-consensus cases. GP4 Type 1 = 
cribriform glands, type 2 = fused glands and type 3 = poorly formed glands. Percentages of 
cases with a GP 4 reported. 
 
Table 5. Number of Gleason pattern (GP) 4 types in consensus and non-consensus cases. 
Percentages of cases with a GP 4 reported. 
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Figure 1A. Gleason pattern (GP) 4 of cribriform type (Type 1). B. GP 4 of fusion type (Type 
2). C. GP 4 with incomplete glands (Type 3). 20X lens magnification in A - C. D. Needle 
biopsy with cancer encircled by red line. Overview to the left, medium slide viewer 
magnification to the right. E. Areas of GP 4 marked with green lines by individual observers. 
F. Marked areas were added on top of each other to produce a heat map showing the 
frequency with which a certain GP was assigned within the biopsy core. The darker green, the 
more often a GP 4 was assigned.  
 
Figure 2A. Consensus case of Gleason score (GS) 3+3=6. 10X lens magnification. B. The 
same consensus case of GS 3+3=6. Most glands are circumscribed and well-defined. Arrow 
indicates a few epithelial strands that can be overlooked, as they possibly represent tangential 
cuts. To be ignored such structures must be only occasional finding. 20X lens magnification. 
C. Consensus case of GS 3+3=6. 10X lens magnification. D. The same consensus case of GS 
3+3=6. Arrow indicates a few seemingly fused glands. When only occasional merged 
glandular structures are found, they should not be interpreted as a fusion pattern, as they 
possibly represent tangential cuts. 20X lens magnification. E. Consensus case of GS 3+4=7. 
10X lens magnification. F. The same consensus case of GS 3+4=7. Some glands are 
circumscribed and well-defined. However, arrow indicates poorly formed glands that are too 
abundant to be and dispersed throughout the visual field to be overlooked. The 2005 ISUP 
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Gleason score categories 
Case 5-6 7 (3+4) 7 (4+3) 8 9 Agreement (%) 
1 12 3 0 0 0 80 
2 0 10 2 3 0 67 
4 2 10 3 0 0 67 
6 2 11 1 0 1 73 
10 13 2 0 0 0 87 
12 1 11 1 2 0 73 
14 0 1 13 0 1 87 
15 1 10 3 1 0 67 
16 0 13 1 1 0 87 
17 11 3 1 0 0 73 
18 10 4 1 0 0 67 
19 11 4 0 0 0 73 
21 1 0 11 3 0 73 
22 1 14 0 0 0 93 
23 12 3 0 0 0 80 
 
 
Table 1. Fifteen consensus cases with at least 67% agreement for Gleason score (GS) 
categories. Number of votes for most commonly assigned grade shown in bold font. 
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Gleason score categories 
Case 5-6 7 (3+4) 7 (4+3) 8 9 Agreement (%) 
3 8 7 0 0 0 53 
5 2 5 3 2 3 33 
7 0 6 8 1 0 53 
8 0 6 8 1 0 53 
9 2 9 1 3 0 60 
11 0 2 8 3 2 53 
13 8 7 0 0 0 53 
20 6 7 2 0 0 47 
24 0 0 4 3 8 53 
25 7 6 1 1 0 47 
 
 
Table 2. Ten non-consensus cases with agreement for Gleason score (GS) categories in less 






 Difficulty scores    
 1 2 3 Total Mean p value 
Consensus 65% (126) 27% (53) 8% (16) 195 1.44 0.003 Non-consensus 48% (62) 38% (50) 14% (18) 130 1.66 
Total 58% (188) 32% (103) 10% (34) 325   
p value       
 
 
Table 3. Difficulty scores in 15 consensus and 10 non-consensus cases. Score 1 = only one 
Gleason score (GS) was possible, score 2 = another GS was considered but the pathologist 
was convinced that the selected GS was the best choice and score 3 = uncertain if the selected 






 Type of Gleason pattern 4   
 1 2 3 Total p value 
Consensus 24% (31) 81% (106) 67% (88) 131 0.38 Non-consensus 35% (34) 94% (91) 66% (64) 97 
Total 28% (65) 86% (197) 67% (152) 228  





Table 4. Gleason pattern (GP) 4 types in consensus and non-consensus cases. GP4 Type 1 = 
cribriform glands, type 2 = fused glands and type 3 = poorly formed glands. Percentages of 





 Number of Gleason Pattern 4 Types  
 1 2 3 Total p value 
Consensus 39% (51) 50% (66) 11% (14) 131 0.03 Non-consensus 28% (27) 50% (48) 23% (22) 97 
Total 34% (78) 50% (114) 16% (36) 228  





Table 5. Number of Gleason pattern (GP) 4 types in consensus and non-consensus cases. 
Percentages of cases with a GP 4 reported. 
 
 
 
 


